This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Microsoft Teams is a great example – during the pandemic, ‘Teams’ revolutionised communication across the NHS, but many staff didn’t receive formal training on using it effectively. In response to this, the Leeds Teaching Hospitals NHS Trust (LTHT) pharmacy team has recently launched its ‘Digital Induction’ document.
They recommended approaching SDOH conversations with empathy, an understanding of community resources, and open communication with the health care team. 4 “We're talking about food security, we're talking about aging programs, we're talking about education, and community resources. The Mount Sinai Hospital.
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value from 2023 to 2024, reaching a total deal value of $2.81bn, according to GlobalData’s Pharma Intelligence Center Deals Database.
Find out more Introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), it will allow patients to receive personalised treatments made at their hospital, clinic or near their homes. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!
On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
In a letter sent to the company, the lawmaker maintained that the decision to discontinue its inhaler in January 2024 has since had “life-threatening consequences for patients” and contributed to a spike in hospitalizations.
It involved pharmacist, hospital doctor and GP training on delivering structured medicine reviews and managing inappropriate polypharmacy. These impacts build upon the unique skill sets of pharmacy teams, including those within hospital settings, and embed medicines optimisation at the heart of patient care.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Hospitalization occurs in 1% to 4% of cases, mostly involving immunocompromised individuals. April 12, 2024. While most experience shingles only once, recurrence is possible. The most common complication is postherpetic neuralgia, affecting 10% to 18% of cases, particularly among older adults. News Release. July 26, 2021.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
The financial conditions outlined in the extended agreement covering the three new ADC projects remain consistent with those specified in the original agreement signed in January 2024 for the initial three projects. In September 2024, Orion entered a partnership with Aitia to leverage AI in drug discovery and simulation in the oncology field.
In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. We may still continue to send you service-related and other non-promotional communications. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!
The findings highlight that there remain communication gaps between oncology providers and patients and that opportunities exist for pharmacists to counsel newly diagnosed oncology patients on their fertility preservation options. Materials and Methods This study design was descriptive, nonexperimental, and retrospective.
If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations.
The National Child Mortality Database report on child deaths related to asthma and allergies was released in December 2024, providing sobering insights. Key findings in this review emphasised that most of these children and young people died before reaching the hospital, with 46% receiving inadequate asthma care.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
These job duties each require different skill sets, from writing and verbal communication to process development, technical aptitude, and deep clinical expertise. August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. However, one person cannot do all these things well. Accessed May 15, 2025.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
In June 2024, the company opened a new facility at the same site, which has already begun producing high-quality prefillable glass syringes. By GlobalData Learn more about Strategic Intelligence SCHOTT Pharma CEO Andreas Reisse stated: “To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
The investment represents a substantial capital infusion to the $3.5bn announced in November 2024. AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). Give your business an edge with our leading industry insights.
Communication with public health authorities and use or precautionary measures to prevent spread is very important. CDC recommends people immediately seek care by contacting their healthcare provider if they think themselves or their child has become exposed to measles. Measles is a mandatory and immediately notifiable disease. 7 March 2025.
Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. Keytruda, approved to treat a range of solid tumours, was the top selling drug in the world in 2024, netting over $29bn in annual sales. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
We may still continue to send you service-related and other non-promotional communications. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. For more information relating to our privacy practices, we invite you to review our privacy policy. Sign up for our daily news round-up!
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Indeed the $9.5bn in sales it generated in 2024, which includes revenue from a high-dose version, means it is one of the top-selling drugs in the world. Eylea’s glory days ending Alvotech is just the latest pharma company to spur an Eylea biosimilar into the European market after Bayer’s blockbuster lost regulatory exclusivity in mid-2024.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
Madrigal accessed a large US market when it won accelerated US Food and Drug Administration (FDA) approval in March 2024 for the first MASH treatment in the region. in 2024, with $103.3m If approved in Europe, Rezdiffra would have the same indication. Don’t let policy changes catch you off guard. of that coming in Q4 alone.
The spray’s UK approval follows its launch in Spain in 2024 and in Germany last month. ALK signed an agreement with ARS for the exclusive licensing and commercialisation rights to EURneffy in the UK and EU last year. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Sign up for our daily news round-up!
By GlobalData Learn more about Strategic Intelligence These concerns were made clear on 14 April 2024, when the European Parliament assigned its position of a baseline RDP at 7.5 Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Give your business an edge with our leading industry insights.
Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content